ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075

ALNA stock is trading at $0.075 on the NASDAQ intraday session on 12 Feb 2026, reflecting a +3.16% move as volume spikes to 252,311,606 shares. This makes Allena Pharmaceuticals, Inc. (ALNA) one of the most active small-cap names today in the United States healthcare tape. Traders are reacting to heavy intraday swings between a day low $0.06 and a day high $0.146, while fundamentals show a small cash runway and negative EPS. We use real-time data and Meyka AI’s market tools to connect the trading activity to valuation and near-term catalysts.

ALNA stock intraday price action and volume

Allena Pharmaceuticals, Inc. (ALNA) is trading at $0.075 on NASDAQ with a one-day change of +3.16% and a traded volume of 252,311,606 shares. The stock opened at $0.064 and has moved between a day low of $0.060 and a day high of $0.146, showing elevated intraday volatility.

High volume on low-priced biotech names often signals short-term retail interest or news-driven flows rather than institutional repositioning. For intraday traders, the spread between $0.060 and $0.146 offers clear intra-session support and resistance reference points.

Company profile, pipeline and sector context

Allena Pharmaceuticals, Inc. develops oral enzyme therapeutics for rare metabolic and kidney disorders, led by candidate ALLN-346 for hyperuricemia in advanced chronic kidney disease. The company is small with 12 full-time employees and is positioned in the Biotechnology industry within the Healthcare sector on the NASDAQ exchange.

Biotech peers in the sector are trading with higher average market caps and more liquidity. ALNA’s intraday activity should be viewed in the context of sector sentiment, where early-stage clinical readouts and licensing news typically drive outsized moves.

Financials and valuation snapshot for ALNA stock

Most recent reported metrics show EPS of -0.64 and a trailing P/E of -0.12, reflecting negative earnings. Cash per share is about $0.92 and book value per share is $0.58, while the current ratio is 2.11, indicating short-term liquidity coverage.

Key ratios underline development-stage status: operating cash flow per share is -1.41, free cash flow per share is -1.43, and enterprise value is reported negative at roughly -$29,461,000, which signals balance-sheet nuances for microcap biotechs. Investors should weigh cash runway and clinical milestones before sizing positions.

Technical cues and trading signals

Intraday technicals show rapid swings and a stretched intraday high at $0.146 vs the current price $0.075, signaling short-term momentum but mixed trend conviction. Average volume data is limited, so the high raw volume today is the best immediate signal for liquidity.

For traders, watch short-term support near $0.060 and resistance near $0.146. Use tight risk controls because volatility is high and the float and shares outstanding data are limited for accurate free-float estimates.

Meyka AI rating and analyst consensus for ALNA

Meyka AI rates ALNA with a score out of 100: 62.59 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth.

This grade is informational only. These grades are not guaranteed and we are not financial advisors. Traders should combine this rating with clinical milestones and cash runway checks before making investment decisions.

Risks, catalysts and near-term outlook for ALNA stock

Primary risks include clinical trial outcomes, limited public float liquidity, and continued negative earnings that pressure valuation. Catalysts that could lift ALNA include positive ALLN-346 data, licensing deals, or balance-sheet improvements through financings.

Given the microcap biotechnology profile, expect outsized intraday moves around any regulatory or clinical news. Position sizing and stop-loss discipline are key for managing ALNA trading risk.

Final Thoughts

ALNA stock is a highly active microcap on NASDAQ today, trading at $0.075 with heavy volume of 252,311,606 shares and intraday swings from $0.060 to $0.146. Financial metrics show negative EPS of -0.64, a current ratio of 2.11, and cash per share near $0.92, which points to some liquidity but continued operating cash burn. Meyka AI’s forecast model projects a 12-month base-case target of $0.18, a bear target of $0.04, and a bull target of $0.40; the base-case target implies an upside of 140.00% versus the current price $0.075. Forecasts are model-based projections and not guarantees. For intraday most-active trading, use the intraday support at $0.060 and resistance at $0.146 to guide entries and exits, and prioritize event-driven risk controls. Meyka AI provides this as AI-powered market analysis to connect trading flows with fundamentals and catalysts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.